You are here

World’s First Phase III Clinical Trial of Regenerative Medicine for Heart Failure

Bone marrow cells are ‘reprogrammed’ to replace damaged heart cells (Nov. 22)

The world’s first phase III study of a regenerative medicine product targeting heart failure — the Congestive Heart FAilure Cardiopoietic Regenerative Therapy (CHART-1) trial — has been initiated in Europe. The study is investigating C3BS-CQR-1 (Cardio3 BioSciences), an autologous stem-cell product.

In the phase III prospective, multicenter, randomized, double-blind trial, C3BS-CQR-1 will be compared with sham treatment in a minimum of 240 patients with chronic advanced symptomatic heart failure. The study’s primary endpoint is a composite of mortality, morbidity, quality of life, the 6-minute walk test, and left ventricular structure and function at 9 months post-procedure.

C3BS-CQR-1 therapy involves taking stem cells from a patient’s bone marrow and “reprogramming” those cells through a process called cardiopoiesis so that the marrow cells can develop into new heart cells that behave identically to those lost to heart disease. These so-called cardiopoietic cells are then injected back into the patient’s heart through a minimally invasive procedure using a catheter, with the aim of repairing damaged tissue and improving heart function and patient clinical outcomes.

C3BS-CQR-1 is the result of years of research conducted at the Mayo Clinic in Rochester, Minnesota, and at clinical centers in Belgium. The new phase III trial builds on the results of a phase II study conducted in Europe in 2009 and 2010.

Source: Cardio3 BioSciences; November 22, 2012.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress